**ABSTRACT**  
OPS-2071 is a novel quinolone antibacterial agent characterized by low oral absorption that reduces the risk of adverse events typical of fluoroquinolone class antibiotics. The *in vitro* and *in vivo* antibacterial activities of OPS-2071 against *Clostridioides difficile* were evaluated in comparison to vancomycin and fidaxomicin. OPS-2071 exhibited potent antibacterial activity against 54 clinically isolated *C. difficile* strains with a MIC of 0.125 μg/ml (MIC₅₀) and 0.5 μg/ml (MIC₉₀), making it more active than vancomycin on a concentration basis (MIC₅₀, 2 μg/ml; MIC₉₀, 4 μg/ml) and comparable to fidaxomicin (MIC₅₀, 0.063 μg/ml; MIC₉₀, 8 μg/ml). OPS-2071 showed equally potent antibacterial activity against both hypervirulent and nonhypervirulent strains, while a significant difference in susceptibility to fidaxomicin was observed. Spontaneous resistance to OPS-2071 and vancomycin was not observed; however, resistance to fidaxomicin was observed at 4 × MIC. The mutant prevention concentration of OPS-2071 was 16-fold lower than those of fidaxomicin and vancomycin, and the postantibiotic effect of OPS-2071 was longer than those of fidaxomicin and vancomycin. Also, OPS-2071 showed low systemic exposure, with OPS-2071 concentration of 0.125 μg/ml and comparable to that of fidaxomicin (MIC₅₀, 0.063 μg/ml; MIC₉₀, 8 μg/ml). OPS-2071 showed significant *in vivo* efficacy at 0.0313 mg/kg/day (50% effective doses), 39.0-fold and 52.1-fold lower than those of vancomycin and fidaxomicin, respectively, in a hamster model of *C. difficile* infection. OPS-2071 has the potential to become a new therapeutic option for treating *C. difficile* infection.

**KEYWORDS**  
OPS-2071, anti-*Clostridioides difficile* agent, new quinolone

---

**Many commercially available antibiotics have the potential to cause diarrhea during treatment of infectious diseases (1), and they often disrupt the normal balance of intestinal flora. This can lead to an increase in pathogenic bacteria that may eventually induce so-called antibiotic-associated diarrhea (AAD). One of the most important causes of AAD is expansion of *C. difficile*, as it is resistant to many currently available antibiotics. It is specifically designated *C. difficile* infection (CDI) or *C. difficile*-associated diseases (CDAD), which are implicated in 10 to 25% of AAD and the most prevalent infective cause of AAD (2, 3). In 2011, the estimated incidence of CDI in the United States was 453,000 and the estimated annual mortality was 295,000 (4).**
C. difficile is capable of producing three toxins, toxin A (TcdA), toxin B (TcdB), and C. difficile transferase toxin (CDT). These toxins are closely associated with certain clinical symptoms (5). In the early 2000s, hypervirulent strains such as the PCR ribotype 027, referred to as BI/NAP1/027, emerged and spread rapidly (6, 7). The BI/NAP1/027 strain produces all three of the toxins referred to above. They damage the gut barrier, leading to severe enterotoxicity in humans, and the BI/NAP1/027 strain is characterized by high-level fluoroquinolone resistance (8, 9).

Since the toxins of C. difficile damage the intestinal epithelial barrier and promote mucosal inflammation, CDI affects gut-related diseases. There are many reports describing how CDI dramatically increases in patients with inflammatory bowel disease (IBD). Consequently, morbidity, mortality, the need for surgery, and health care costs have been increasing due to CDI in IBD patients compared with IBD patients who are not infected (10–14). Therefore, there is general agreement that CDI is the most common gastrointestinal infection in patients with IBD. Treatment of CDI is a critical subject for gut-related diseases such as IBD.

Given the current range of treatment options, vancomycin and fidaxomicin are the preferred first-line therapeutic agents for the initial episode of CDI, but their use in cases of multiple recurrences is not well established. Metronidazole is also used to treat CDI but is only recommended for treatment of the initial episode in nonsevere cases (15). Over the preceding decade, new CDI treatments have been developed, such as fecal microbiota transplantation (FMT). FMT restores the diversity of the gut microbiota and has achieved cure rates exceeding 85%. However, there is a risk that the donor stool may cause infection in immunocompromised patients (16). While FMT is a promising therapy, it has not been widely accepted for broad clinical use. Thus, there is a pressing need for the development of a new therapeutic agent for CDI that can successfully address these issues.

OPS-2071, 7-(6-amino-5-cyanopyridin-3-yl)-1-cyclopropyl-6-fluoro-8-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid, is a novel quinolone antibacterial agent (Fig. 1) developed at Otsuka Pharmaceutical Co., Ltd., targeting intestinal infection pathogens, including C. difficile. It has decreased potential for absorption from the intestine, which in turn reduces the adverse events commonly associated with the fluoroquinolone class of antibiotics.

In order to assess the potential utility of OPS-2071 against CDI, the evaluation of in vitro and in vivo antibacterial activity, spontaneous resistance, and pharmacokinetics was performed and compared to reference compounds.

RESULTS

Antibacterial activity of OPS-2071 against 54 clinically isolated strains of C. difficile. The in vitro antibacterial activities of OPS-2071 and other relevant compounds against 54 clinically isolated C. difficile strains obtained from Aino Hospital (Osaka, Japan) and Miroku Laboratory (Nagano, Japan) are shown in Table 1 and Table S1 in the supplemental material. As expected, commonly used quinolone antibiotics such as ciprofloxacin and levofloxacin are inactive against C. difficile isolates. Compared with conventional therapeutic agents (vancomycin, metronidazole, and fidaxomicin), the MIC50 and MIC90 of OPS-2071 were, respectively, 16-fold and 8-fold lower than those of vancomycin and metronidazole and 2-fold higher and 16-fold lower than that of fidaxomicin. Using the method described by the Clinical and Laboratory Standards Institute (CLSI), the MICs of OPS-2071, vancomycin, and fidaxomicin against a quality control
strain, *C. difficile* ATCC 700057, were 0.031, 2, and 0.063 µg/ml, respectively (17). These results indicate that OPS-2071 possesses comparable activity to that of fidaxomicin and was more active than both vancomycin and metronidazole against *C. difficile* on a concentration basis.

**Antibacterial activity comparison between 20 hypervirulent and 42 nonhypervirulent strains of *C. difficile***. In order to compare the antibacterial activity of OPS-2071 between hypervirulent and nonhypervirulent strains, 20 hypervirulent and 42 nonhypervirulent strains were obtained from the University of Western Australia (Perth, Australia) and Rakuno Gakuen University (Hokkaido, Japan). *C. difficile* can be characterized by PCR ribotyping (8). Several ribotypes are known to be epidemiologically hypervirulent, high-toxin-producing strains. In addition, these strains were reported to be highly resistant to existing fluoroquinolones (1, 18–20). We tested the *in vitro* antibacterial activity against 62 strains of *C. difficile*, which were genetically characterized and different from the 54 strains in Table 1, including 20 epidemiologically hypervirulent strains (PCR ribotype 018, 2 strains; 023, 2 strains; 027, 4 strains; 056, 2 strains; 078, 7 strains; and 244, 3 strains) (6, 7, 21–23). There was no significant difference in the susceptibility to OPS-2071 and vancomycin between hypervirulent and nonhypervirulent strains (Table 2); however, significant differences in susceptibility to fidaxomicin (*P* < 0.01) and metronidazole (*P* < 0.05) were found (Wilcoxon rank sum test). The ribotypes of these 20 hypervirulent strains are shown in Table S2.

**Bactericidal activity**. The inhibitory and bactericidal activities of OPS-2071 and other drugs against 10 of the 54 clinical isolates are summarized in Table 3. These 10 clinical isolates were selected from 44 of 54 clinical isolates, described in Table 1, based on the inclusion criterion of a smaller MIC90 to OPS-2071, vancomycin, metronidazole, and fidaxomicin. The minimum bactericidal concentration of OPS-2071 required to eradicate 90% of organisms (MBC90) was the same as the MIC90. In contrast, the MBC90 of the other drugs was 1- to 2-fold higher than the corresponding MIC90 values. These data indicate that OPS-2071 has bactericidal activity against clinically isolated strains of *C. difficile* at a concentration equivalent to the MIC.

**Inhibition of DNA gyrase activity**. DNA gyrase and DNA topoisomerase IV are, respectively, the primary and secondary targets of fluoroquinolones. In *C. difficile*, evidence exists that the secondary target is absent (24). To evaluate the mechanism of action, the ability of OPS-2071 to inhibit DNA gyrase was evaluated and compared with that of existing quinolones in *C. difficile*. As expected, the 50% inhibitory concentration (IC50 [µg/ml]) of OPS-2071 was much lower than those of ciprofloxacin and levofloxacin (OPS-2071 IC50 0.23 [range, 0.17–0.32]; ciprofloxacin IC50 8.59 [4.23–22.29]; levofloxacin IC50 11.49 [6.08–46.29]).

**Killing kinetics.** Time-kill curves for OPS-2071, vancomycin, metronidazole, and fidaxomicin were determined using *C. difficile* ATCC 700057 (Fig. 2). In order to do this assay, the MICs of OPS-2071, vancomycin, metronidazole, and fidaxomicin against the strain were retested for this assay, and the MICs determined by a broth dilution method were 0.03, 4, 0.5, and 0.03 µg/ml, respectively. After the addition of OPS-2071 at concentrations higher than the MIC, the numbers of viable bacteria decreased rapidly, with a 2-log reduction in the first 2 h and a continued decrease to an undetectable

### Table 1 MICs for 54 clinically isolated strains of *C. difficile*

<table>
<thead>
<tr>
<th>Antibiotic</th>
<th>MICs (µg/ml)</th>
<th>MIC50</th>
<th>MIC90</th>
<th>MIC range</th>
</tr>
</thead>
<tbody>
<tr>
<td>OPS-2071</td>
<td>0.125</td>
<td>0.5</td>
<td>0.016–1</td>
<td></td>
</tr>
<tr>
<td>Ciprofloxacin</td>
<td>32</td>
<td>128</td>
<td>16–128</td>
<td></td>
</tr>
<tr>
<td>Levofloxacin</td>
<td>128</td>
<td>&gt;128</td>
<td>4 to &gt;128</td>
<td></td>
</tr>
<tr>
<td>Vancomycin</td>
<td>2</td>
<td>4</td>
<td>1 to &gt;128</td>
<td></td>
</tr>
<tr>
<td>Metronidazole</td>
<td>2</td>
<td>4</td>
<td>1 to &gt;128</td>
<td></td>
</tr>
<tr>
<td>Fidaxomicin</td>
<td>0.063</td>
<td>8</td>
<td>0.016 to &gt;128</td>
<td></td>
</tr>
</tbody>
</table>
level within 24 h. After 48 h of incubation, regrowth of the bacteria did not occur. The killing kinetics of fidaxomicin were close to those of OPS-2071. As for vancomycin and metronidazole, these drugs needed over 2-fold MIC for an undetectable level to be reached. The killing kinetics of OPS-2071 showed that the drug is effective against C. difficile.

Frequency of spontaneous resistance. To test the frequency of spontaneous resistance, the MICs were determined for this assay. The MICs of OPS-2071, vancomycin, and fidaxomicin against C. difficile ATCC 700057 were 0.03, 2, and 0.06 µg/ml, respectively. The frequency of spontaneous resistance to OPS-2071 and other compounds are shown in Table 4. No mutants were observed at concentrations of 4-, 16-, and 64-fold MIC of OPS-2071 with a frequency of less than 9.17 × 10⁻³. In contrast, resistant mutants were observed at 4-fold MIC of fidaxomicin. C. difficile strain ATCC 700057 did not show a propensity to develop spontaneous resistance in response to OPS-2071.

Mutant prevention concentration. The mutant prevention concentration (MPC) against C. difficile ATCC 700057 is defined as the minimal concentration at which there is no emergence of resistant bacteria (25). The MPC of OPS-2071, vancomycin, and fidaxomicin are 0.5, 8, and 8 µg/ml, respectively. The MPC of OPS-2071 was the lowest among tested compounds. This study suggests that the risk of emergence of OPS-2071-resistant C. difficile strains is considerably lower than that for vancomycin and fidaxomicin.

Postantibiotic effect of OPS-2071. The postantibiotic effect (PAE) is defined as the

| TABLE 2 MIC distribution of each drug against hypervirulent and nonhypervirulent strains |
|---------------------------------------------|----------------|----------------|----------------|----------------|
|                                      | Cumulative percentage of 62 strains (%)* |
| MIC (µg/ml) | OPS-2071 | Non-hyp (n = 42) | Vancomycin | Non-hyp (n = 42) | Fidaxomicin | Non-hyp (n = 42) | Metronidazole | Non-hyp (n = 42) |
| <0.004 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0.008 | 5 | 5 | 5 | 5 | 5 | 5 |
| 0.016 | 65 | 79 | 80 | 80 | 80 | 80 |
| 0.031 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0.063 | 75 | 88 | 80 | 80 | 80 | 80 |
| 0.125 | 80 | 90 | 80 | 80 | 80 | 80 |
| 0.25 | 100 | 100 | 100 | 100 | 100 | 100 |
| 0.5 | 0 | 0 | 0 | 0 | 0 | 0 |
| 1 | 95 | 95 | 95 | 95 | 95 | 95 |
| 2 | 95 | 95 | 95 | 95 | 95 | 95 |
| 4 | 95 | 95 | 95 | 95 | 95 | 95 |
| 8 | 95 | 95 | 95 | 95 | 95 | 95 |
| >16 | 100 | 100 | 100 | 100 | 100 | 100 |

*MIC values for hypervirulent strains (hyp) and nonhypervirulent (non-hyp) strains were compared for statistical significance using a two-tailed Wilcoxon rank sum test (P < 0.05). n, number of strains which were tested.

| TABLE 3 Comparison of MICs and MBCs of OPS-2071 and other compounds against C. difficilea |
|---------------------------------------------|----------------|----------------|----------------|----------------|
| Compound | MIC Range (µg/ml) | MIC₅₀ | MBC Range (µg/ml) | MBC₉₀ | MBC₉₀/MIC₉₀ |
| OPS-2071 | 0.03–0.25 | 0.5 | 0.5 | 1 | 2 |
| Vancomycin | 2–4 | 4 | 4–8 | 8 | 2 |
| Metronidazole | 1–4 | 4 | 1–4 | 4 | 1 |
| Fidaxomicin | 0.06–0.25 | 0.125 | 0.06–0.25 | 0.25 | 2 |

aOf the 54 clinical isolates used in Table 1, 10 were selected and used for this test.
delayed regrowth or the persistent growth suppression of bacteria after short antimicrobial exposure. The PAEs of OPS-2071 against *C. difficile* were determined and compared with those of other drugs (Table 5). A broth method was used to determine the MICs of OPS-2071, vancomycin, and fidaxomicin against *C. difficile* ATCC 700057. The MICs were 0.06, 4, and 0.06 µg/ml, respectively, and the PAEs of OPS-2071 at 4- and 8-fold the MIC against *C. difficile* (3.93 to 4.04 h) were longer than those of vancomycin (1.03 to 1.25 h) and fidaxomicin (2.86 to 2.77 h). As OPS-2071 showed a longer PAE against *C. difficile* than either vancomycin or fidaxomicin, the duration of OPS-2071's antibacterial efficacy against *C. difficile* can be expected to be longer than that of the other two agents.

**Cytotoxicity assay.** The cytotoxicity of OPS-2071 was determined with the neutral red uptake assay in BALB/3T3 clone A31 cells. OPS-2071 did not show cytotoxicity up to 100 µg/ml (IC50 > 100 µg/ml).

**Pharmacokinetics in the hamster.** OPS-2071 was orally administered at 2 mg/kg. The maximum concentration (Cmax) in the cecal contents reached 42.95 µg/g at 4 h postdose and then decreased to 1.84 µg/g at 24 h postdose (Fig. 3). This concentration was many times higher than the MIC90 and MBC90 of OPS-2071 for *C. difficile*.

**Pharmacokinetics in the rat.** OPS-2071 showed low systemic exposure, with values

### TABLE 4 Frequency of spontaneous resistance against *C. difficile* ATCC 700057

<table>
<thead>
<tr>
<th>Compound</th>
<th>Dose</th>
<th>Test concn (µg/ml)</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>OPS-2071</td>
<td>4 × MIC</td>
<td>0.125</td>
<td>&lt;9.17 × 10⁻⁷</td>
</tr>
<tr>
<td></td>
<td>16 × MIC</td>
<td>0.5</td>
<td>&lt;9.17 × 10⁻⁹</td>
</tr>
<tr>
<td></td>
<td>64 × MIC</td>
<td>2</td>
<td>&lt;9.17 × 10⁻⁹</td>
</tr>
<tr>
<td>Vancomycin</td>
<td>4 × MIC</td>
<td>8</td>
<td>&lt;9.17 × 10⁻⁹</td>
</tr>
<tr>
<td></td>
<td>16 × MIC</td>
<td>32</td>
<td>&lt;9.17 × 10⁻⁹</td>
</tr>
<tr>
<td></td>
<td>64 × MIC</td>
<td>128</td>
<td>&lt;9.17 × 10⁻⁹</td>
</tr>
<tr>
<td>Fidaxomicin</td>
<td>4 × MIC</td>
<td>0.25</td>
<td>1.47 × 10⁻⁷</td>
</tr>
<tr>
<td></td>
<td>16 × MIC</td>
<td>1</td>
<td>&lt;9.17 × 10⁻⁹</td>
</tr>
<tr>
<td></td>
<td>64 × MIC</td>
<td>4</td>
<td>&lt;9.17 × 10⁻⁹</td>
</tr>
</tbody>
</table>
for the area under the concentration-time curve calculated to the last observable concentration at time $t$ (AUC$_t$) after oral and intravenous administration of OPS-2071 at 1 mg/kg of 19.48 and 671.7 ng · h/ml, respectively (Fig. 4). Therefore, the calculated oral bioavailability was 2.9%. In addition, orally administered $^{14}$C-OPS-2071 derived radioactivity was distributed to the large intestine at a high concentration (Fig. 5), and more than 95% of dosed radioactivity was excreted in feces. These results indicate that the low absorption of OPS-2071 makes it suitable for treating CDI.

**In vivo activity in the hamster.** The effectiveness of OPS-2071 and other drugs was assessed in a hamster model of CDI. This model is the current gold standard used to assess potential efficacy in the treatment of CDI (26–29). The survival curve for each drug tested in this study is shown in Fig. 6. After infection, all hamsters treated with vehicle died within 5 days. Compared with the vehicle control, significant efficacy was observed for OPS-2071 at dosages of 0.04 mg/kg and above. In contrast, significant efficacy was observed for vancomycin and fidaxomicin only at dosages of 1 mg/kg and above. The 50% effective doses (ED$_{50}$) of OPS-2071, vancomycin, and fidaxomicin were 0.0313 mg/kg/day (95% confidence interval [CI], 0.0131 to 0.0686 mg/kg/day), 1.22 mg/kg/day (95% CI, 0.597 to 2.39 mg/kg/day), and 1.63 mg/kg/day (95% CI, 0.836 to 3.20 mg/kg/day), respectively. OPS-2071 also had an ED$_{50}$ 39.0-fold lower than that of vancomycin and 52.1-fold lower than that of fidaxomicin.

**DISCUSSION**

*C. difficile* has been reported as an urgent threat to human health by the Centers for Disease Control and Prevention in the United States since 2013 (30). To date, new compounds and new therapies have been developed to treat CDI (16, 26, 31). However, there is no drug presently able to overcome such problems as fulminant life-threatening colitis characterized by high mortality (35 to 50%) and a high rate of recurrence, for which CDI is the cause in 15 to 25% of initial episodes (4). FMT is a new approach showing high cure rates for recurrent CDI (32); however, wide clinical use of FMT is still difficult because the preferred method for FMT administration is yet to be defined (32). Therefore, it is necessary to develop an easy-to-use CDI treatment such as antibiotics used for common infectious diseases. Fluoroquinolone has been used in clinical practice for over 30 years and is well known to be an antibiotic with high killing efficiency against both Gram-positive and Gram-negative bacteria. Regarding adverse events, it is generally well tolerated, and most adverse effects are mild (33). Though fluoroquinolone is still considered to be an important antibiotic for patients with serious infections,
the FDA issued changes to the safety labeling for systemic fluoroquinolone in 2018. Apart from the existing major well-known central nervous system (CNS)-related adverse effects (phototoxicity, QT interval prolongation, and diarrhea), the FDA required that the risk of serious blood sugar disturbances and psychiatric side effects be added to the labeling (34). It is important to note that most of these adverse events, including the newly added risks, are caused by the systemic absorption of antibiotics. Fluoroquinolones are considered to be one of the major antibiotic classes that can induce CDI because predominant strains are resistant to common fluoroquinolones such as ciprofloxacin and levofloxacin (1, 18–20). We approached the development of a new antibiotic with the aim of increasing antibacterial activity against C. difficile by utilizing the quinolone structure and decreasing the oral absorption in order to reduce the risk of adverse events associated with fluoroquinolone class antibiotics. Based on our experience in the area of structure-activity relationships, we succeeded in developing OPS-2071 as a novel fluoroquinolone that demonstrates potent antibacterial activity against C. difficile.

The in vitro activity against clinical isolates was similar to that of fidaxomicin and more potent than that of vancomycin. The MIC₉₀ of fidaxomicin for 54 clinical isolates was 8 μg/ml (Table 1), and the MIC₉₀ for 62 strains was 0.25 μg/ml (Table 2). In contrast to these 62 strains, the 54 clinical isolates included fidaxomicin-resistant strains, and this resulted in the different fidaxomicin MIC₉₀ values. This indicates that there is a greater range of MICs for fidaxomicin in clinical isolates compared to OPS-2071.
Furthermore, while there is no difference in the activity of OPS-2071 between hypervirulent and nonhypervirulent strains, a significant difference in susceptibility to fidaxomicin was observed. Also, MICs of OPS-2071 are not influenced by pH (Table S3). The intraluminal pH changes rapidly from highly acid in the stomach to about pH 6.0 in the duodenum, and the pH gradually increases in the small intestine from pH 6.0 to about pH 7.4 in the terminal ileum. The activity of OPS-2071 is not affected by differences in pH in the gastrointestinal tract.

In addition, OPS-2071 demonstrated bactericidal activity against *C. difficile* at concentrations close to MIC, rapidly reducing the number of the organisms with no regrowth observed after 48 h (Fig. 2). Although each time point represents a single sample, these killing kinetics are reasonable because the trajectories of the kinetics depend on the concentration (MIC values) of these compounds. Since OPS-2071 showed the longest PAE among the tested compounds, this and the other characteristics of OPS-2071 contributed to the ideal bactericidal activity curve portrayed by its inhibition of bacterial regrowth *in vitro*.

With regard to resistance, the frequency of spontaneous resistance was extremely low for OPS-2071, despite inoculation with very high concentrations of *C. difficile*. No spontaneous resistant mutants grew at 4-, 16- or 64-fold the MIC. Furthermore, the MPC value, which has been employed in the evaluation of an antibiotic’s ability to minimize or limit the development of resistant organisms, was the lowest among all tested compounds. The data suggest that *C. difficile* may not readily develop resistance to OPS-2071 in the clinical setting and that the drug is suitable as a monotherapy for the treatment of CDI.

Regarding the pharmacokinetics of OPS-2071, the bioavailability at 1 mg/kg in rats was 2.9%, indicating that OPS-2071 has a low absorption profile in rats. We speculated that this profile may also apply to hamsters, because a high concentration of OPS-2071 was observed in the cecal contents of hamsters (Fig. 3). This characteristic of low absorption of OPS-2071 is desirable for increasing therapeutic efficacy against the onset of *C. difficile* while at the same time reducing the risk of systemic adverse events, reinforcing the evidence that OPS-2071 should be an effective agent for treating CDI.

With respect to the efficacy in animal models, many therapeutic agents have been tested in the hamster model of clindamycin-induced CDI (26–29). Specifically, we organized our animal model with reference to an animal model in which clindamycin is administered 1 day after the *C. difficile* infection (27), because CDI is normally
induced by administration of antibiotics with preexisting C. difficile in the intestine. In addition, the MIC of C. difficile ATCC 43255 to clindamycin is reported as 8 μg/ml (35). Since test compounds were administered for 5 days after 1 mg/kg clindamycin administration, the effect of the clindamycin on other test compounds appears to be very low.

OPS-2071 showed significant efficacy in this model with an effective dose, which was 39.0-fold and 52.1-fold lower than those of vancomycin and fidaxomicin, respectively. Although the in vitro antibacterial activity of OPS-2071 against C. difficile was similar to that of fidaxomicin, in vivo efficacy was demonstrated at a lower dose than that of fidaxomicin. Similar to OPS-2071, absorption of vancomycin and fidaxomicin is also low, and both reach the colon efficiently. The oral bioavailability of vancomycin is <10%, and fidaxomicin is minimally absorbed, with plasma concentrations in the low nanogram per milliliter range or lower (36, 37). The pharmacokinetic (PK) profiles of these three drugs are fairly similar. These results suggested the possibility that the cecal contents affect the antibacterial activity among these three drugs in different manners.

For the data lacking biological replicates in this paper, the limitation as a single data set must be considered. However, we believe that the data are sufficiently reliable considering that they have dose response, time course-dependent changes, or large data sets.

In conclusion, OPS-2071 demonstrated potent in vitro activity against clinical isolates and hypervirulent strains. In vivo efficacy using hamsters was shown at doses 39.0- and 52.1-fold lower than those of vancomycin and fidaxomicin. The data support that OPS-2071 has potential as an agent for treating CDI. The current challenge in treating CDI is the frequency of recurrence (38). One of the main causes of recurrence is the dormancy of C. difficile as spores (39), which can revert back to being an active infection. It is unknown if OPS-2071 eliminates C. difficile, including its spores, an important property central to reducing infection recurrence. Follow-up studies are needed to explore this matter in more depth.

MATERIALS AND METHODS

Antibiotics. OPS-2071 was synthesized by Otsuka Pharmaceuticals. Co., Ltd. (Tokushima, Japan). 14C-OPS-2071 was synthesized by Curachem, Inc. (Chungcheongbuk-do, South Korea). Ciprofloxacin and levofloxacin were purchased from Sigma-Aldrich (St. Louis, MO). Vancomycin was purchased from Fujifilm Wako Pure Chemical Corp. (Osaka, Japan). Fidaxomicin was purchased from Optimer Pharmaceuticals, Inc. (Jersey City, NJ) and extracted and purified at Otsuka Pharmaceuticals, Co., Ltd.

Microorganisms. Clinically isolated strains were obtained with 112 strains in total. We obtained 4 strains from Aino Hospital (Osaka, Japan) and 50 strains from Miroku Medical Laboratory (Nagano, Japan) as shown in Table 1. A total of 17 hypervirulent and 18 nonhypervirulent strains were obtained from the University of Western Australia (Perth, Australia), and 3 hypervirulent and 24 nonhypervirulent strains were obtained from Rakuno Gakuen University (Hokkaido, Japan) as shown in Table 2. ATCC 700057 and ATCC 43255 were purchased from the American Type Culture Collection (ATCC; Manassas, VA).

Animals. All studies were carried out in adherence to the Guidelines for Animal Care and Use (40), which were approved by the Animal Care and Use Committee of Otsuka Pharmaceutical Co., Ltd.

Four to five-week-old, specific-pathogen-free, male golden Syrian hamsters were purchased from Japan SLC, Inc. (Shizuoka, Japan). Five- to six-week-old, specific-pathogen-free, male Sprague-Dawley (SD) rats were purchased from Charles River Laboratories Japan, Inc. Hamsters were housed in mouse hi-PSF cages (CLEA Japan, Inc.) during the infection study and Econ TPX cages (CLEA Japan, Inc.) during the PK study. SD rats were housed in stainless bracket cages (Nihon Cage Co., Ltd.) and Econ TPX cages (CLEA Japan, Inc.) Animals were fed with a certified diet (CRF-1; Oriental Yeast Co., Ltd.) ad libitum. Water, food, and bedding were autoclaved prior to use. Animals were allowed to acclimate in the animal facility, in which environmental controls were set to the following conditions: a temperature of 23 ± 2°C, humidity of 60% ± 10%, and a 12 h light-dark cycle (light period, 7 a.m. to 7 p.m.) for more than 1 week. Ten randomly selected hamsters per group were used for the experimental infection model. Five hamsters per group and three rats per group, randomly selected, were used for the pharmacokinetic study.

Determination of antibacterial activity. MICs obtained using the agar dilution method were determined visually as described for the CLSI method (41, 42). MICs obtained using the broth dilution method were determined visually based on the CLSI method except for using Gifu anaerobic medium (GAM) broth instead of supplemented Brucella broth (41, 42).

MBC testing. From among 54 strains, the 10 C. difficile strains sensitive to the antibiotics being tested were selected for the MBC test. Using the agar dilution method, these sensitivities were determined based on the MIC for OPS-2071, vancomycin, fidaxomicin, and metronidazole as shown in Table
1. In this test, MIC testing was performed using the broth dilution method as recommended in the CLSI (41). After the MICs were determined, 10 μl of the bacterial suspension from the MIC test tube was inoculated onto agar plates and incubated at 37°C. The bacterial colonies were then counted and bacterial numbers were calculated. The MBC was considered to be the lowest concentration of the antibiotics that prevented growth and reduced the inoculum by >99.9% within 48 h, irrespective of counts of survivors at higher antibiotic concentrations.

**Killing kinetics.** The bacterial suspensions of *C. difficile* ATCC 700507 in GAM broth were precultured for 2 h, and the test agents were added to the test tubes at concentrations of 0.5, 1, 2, 4, and fold MIC. The test tubes were incubated for 48 h. The CFU/ml values of the bacterial suspensions were calculated at 0, 2, 4, 6, 24, and 48 h by culturing each 10-fold dilutions on GAM agar plates at 37°C under anaerobic conditions and then counting the number of growing colonies. The CFU/ml value at each time point is from one sample of datum.

**Inhibition of DNA gyrase activity.** The subunits A and B of DNA gyrase of *C. difficile* were purchased from Inspiralis Ltd. (Norwich, UK). The supercoiling activity of DNA gyrase was determined as described previously (43). The inhibitory effect of compounds was assessed by determining the concentration required to inhibit 50% of the enzyme (IC50).

The gyrase supercoiling reaction mixtures (30 μl), which contained gyrase (1 unit) and relaxed pBR322 DNA (500 ng), with or without drug solution, were incubated at 37°C for 30 min. The assay reaction mixture was analyzed by electrophoresis. The gels were stained with ethidium bromide, and the density of the supercoiled plasmid was obtained using a UV illuminator. The image of the supercoiled plasmid was analyzed using image processing software (ImageJ 1.50i; National Institutes of Health, USA). The IC50 was defined as the concentration that caused 50% inhibition of the supercoiled plasmid.

**Frequency of spontaneous resistance.** The frequency of spontaneous *C. difficile* ATCC 700507 resistant to OPS-2071, vancomycin, metronidazole, and fidaxomicin was measured by inoculating the bacterial suspension onto a supplemented Brucella agar (Brucella agar with 5 μg/ml of hemin, 1 μg/ml of vitamin K1, and 5% laked horse blood) plate containing antibiotics at 4, 16-, and 64-fold the agar dilution MIC. The frequency of spontaneous resistance to each compound was calculated as the number of resistant colonies formed per the number of inoculated bacteria.

**Mutant prevention concentration (MPC).** The mutant prevention concentration was determined using MIC testing method as described by the CLSI (41). The MIC values of grown colonies were compared to determine which bacteria were resistant. The MFC was defined as the lowest concentration that prevented the growth of resistant bacteria.

**Determination of PAE.** *C. difficile* ATCC 700507 was cultured in GAM agar at 37°C and incubated for 24 h. The bacterial suspension was serially diluted in 10-fold dilutions in GAM broth and then diluted in GAM broth to approximately 106 CFU/ml. The bacterial suspensions were preincubated at 37°C for 1 h. Before and after preincubation, the CFU/ml was determined using serial cultures of 10-fold dilutions on GAM agar at 37°C. After preincubation, test and reference solutions were added to each bacterial suspension in a test tube, and the suspensions were cultured for 1 h. After exposure to the test compounds, bacterial suspensions were washed with GAM broth and cultured for 6 h. In order to calculate the CFU/ml of these suspensions every hour, serial 10-fold dilutions were cultured on agar plates. The PAE was defined according to Craig and Gudmundsson as PAE = T − C, where T is the time required for the viable counts of the exposed bacteria to increase by 1 log10, above the counts observed immediately after washing, and C is the corresponding time for the antibiotic unexposed controls (44). The PAEs of OPS-2071 were compared with other compounds at 4 × and 8 × the MIC.

**Cytotoxicity assay.** The BALB/c mouse fibroblast cell line, BALB/3T3 clone A31 cell (JCRB9005), was obtained from the Health Science Research Resources Bank (Osaka, Japan) and was cultured in Dulbecco's modified Eagle's medium (Sigma-Aldrich) supplemented with 10% heat-inactivated newborn calf serum (Gibco), 100 μU/ml penicillin and 100 μg/ml streptomycin (Sigma-Aldrich). The neutral red uptake assay was adapted to determine cytotoxicity as follows (45). The cells were seeded into a 96-well plate at 1 × 104 cells/well in 100 μl of culture medium and incubated for 24 h at 37°C in 5% CO2. After the culture medium was removed, cells were treated with negative control (dimethyl sulfoxide) and OPS-2071 (1.77 to 100 μg/ml, six wells/dose) in Earle's balanced salt solution (EBSS; Sigma-Aldrich) supplemented with 10 mmol/liter N-(2-hydroxyethyl)piperazine-N′-(2-ethanesulfonic acid) (HEPES; Sigma-Aldrich) for 1 h and 30 min, followed by incubation with culture medium for 21 h. The culture medium was replaced with 50 μg/ml neutral red (Sigma-Aldrich) containing culture medium and incubated for 3 h. The cells were washed with Dulbecco's phosphate-buffered saline (Gibco), and neutral red was extracted with extraction solution (50% ethanol, 49% water, and 1% acetic acid). Absorbance at 540 nm was measured using a Molecular Devices Emax plate reader (Molecular Devices, San Jose, CA), and cell viability was calculated.

**Pharmacokinetics in the hamster.** OPS-2071 was orally administered to 2 mg/kg to male Syrian hamsters, and the cecal contents were collected 0.5, 1, 2, 4, 8, 24, 48, and 72 h postdose (n = 5 for each time point). After homogenizing with saline and treatment using acetonitrile-formic acid (100:1 [vol/vol]), the OPS-2071 concentration in cecal contents was determined using a validated liquid chromatography-electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS) method. The mass spectrometer 4000 QTRAP (AB Sciex Pte. Ltd.) and high-performance liquid chromatography Prominence UFLC system (Shimadzu Corp.) were used. The pharmacokinetic (PK) parameters (Cmax) were determined with WinNonlin professional software version 6.3, (Pharsight Corp.).

**Pharmacokinetics in the rat.** OPS-2071 was orally or intravenously administered at 1 mg/kg to male SD rats, and plasma was collected 0.5, 1, 2, 4, 6, 8, 12, 24, 48, and 72 h postdose (oral, n = 3 for
each time point) or 0.083, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, and 72 h postdose (intravenous, n = 3 for each time point). After solid-phase extraction, the OPS-2071 concentration in plasma was determined by a validated LC-MS/MS method, and bioavailability was calculated. The mass spectrometer QTRAP 5500 (AB Sciex Pte. Ltd.) and high-performance liquid chromatography Prominence UFLCXR system (Shimadzu Corp.) were used. The PK parameters (AUC) were determined with the same WinNonlin professional software, and the bioavailability was calculated from AUC_{oral} and AUC_{intravenous}.

14C-OPS-2071 was orally administered at 3 mg/kg to male SD rats. Blood was collected 1, 2, 4, 6, 8, 12, 24, 72, and 168 h postdose (n = 3 for each time point), the stomach, small intestine, and large intestine were collected 1, 4, 8, 24, 72, and 168 h postdose (n = 3 for each time point), and feces were collected up until 168 h postdose (n = 3). The collected blood, stomach, small intestine, large intestine, and feces were dissolved in a tissue solubilizer, and radioactivity was measured using a liquid scintillation counter LSC-6101 (Aloka Co., Ltd.) to calculate the concentration. Cumulative excretion in feces was calculated from fecal radioactivity concentrations.

In vivo hamster model of C. difficile infection. C. difficile ATCC 43255 was cultured on GAM agar, and a bacterial suspension was prepared in saline (26). The MIC values of OPS-2071, vancomycin, and fidaxomicin against C. difficile ATCC 43255 are 0.016, 2, and 0.06, respectively. Hamsters were infected using oral gavage with 0.5 ml of suspension containing approximately 10^6 CFU of C. difficile (day −1). The next day, the animals were administered clindamycin phosphate (0.2 mg/ml in water) by oral gavage at a dose of 5 ml/kg of body weight, for a final dose of 1 mg/kg (day 0). The animals were allocated to the test groups using a stratified randomization method based on the body weight of each infected animal. The test compounds were administered by oral gavage once daily for 5 days (OPS-2071, 0.008 to 1 mg/kg; fidaxomicin, 0.04 mg/kg to 5 mg/kg; vancomycin, 0.04 to 5 mg/kg [5-fold dilution]). Infected control animals were administered 5% (wt/vol) gum arabic solution by oral gavage. Animals were observed at least once daily for mortality and the presence or absence of diarrhea, and mortality was recorded once daily. From the perspective of animal protection, any significantly debilitated hamsters were euthanized for humane reasons. The cecal contents of dead animals were tested for toxin A and toxin B using C.Diff Quik Chek Complete (Abbott Diagnostics Medical Co., Ltd., Tokyo, Japan) to confirm that the death of the animal was due to CDI.

Statistical analysis. Statistical analyses were conducted using SAS software release 9.3 (SAS Institute Japan). The significance level of the test was set at 5%.

Differences between hypervirulent and nonhypervirulent strains were statistically analyzed using two-tailed Wilcoxon rank sum tests.

The statistical significance of OPS-2071, fidaxomicin, and vancomycin treatment was analyzed at all doses against vehicle. Survival curves were estimated for each group using the Kaplan-Meier method. Differences in survival homogeneity in each group were evaluated with a log-rank test with Dunnett-type (two-sided) comparison.

The effective dose at 50% (ED_{50}) of the dose response was generated for OPS-2071, vancomycin, and fidaxomicin on day 20, and its 95% confidence interval was determined using a probit method.

SUPPLEMENTAL MATERIAL
Supplemental material is available online only.

SUPPLEMENTAL FILE 1, PDF file, 0.4 MB.

ACKNOWLEDGMENTS
Funding for this work was provided by Otsuka Pharmaceutical Co., Ltd.

We thank Thomas Riley, the Western Australia and Rakuno Gakuen University, for providing hypervirulent and nonhypervirulent C. difficile and Aino hospital, Osaka City Environmental Science Research Institutes, and Miroku Laboratory for providing clinically isolated C. difficile strains. We also thank Toshio Shinohara, Shunpei Ishikawa, Motohiro Itotani, Norimitsu Hariguchi, Izuru Nakamura, Yohei Hayashi, Kuniko Hirota, Mamoru Fujii, Yusuke Inoue, Soichiro Akamatsu, and Kazuyuki Fujii for technical assistance and Keiji Kakumoto for technical support on statistical analyses. In addition, we thank Noriyuki Koyama, David Oldach, and Xiuhao Chen for critical review of the manuscript.

All authors actively participated in the OPS-2071-related studies described in this article. D. Oka, N. Yamaya, T. Kuno, Yuta Asakawa, T. Shiragiku, L. Cheng, J. Xue, and K. Ohguro performed the experiments and analyzed the data. H. Miyamoto and J.-F. Cheng took the lead in the optimization of the compounds that resulted in the development of OPS-2071. A. Mamuti, F. Ye, J. Sun, and Y. Uematsu contributed in the synthesis and purification of OPS-2071 derivatives. M. Matsumoto oversaw the C. difficile drug discovery project. D. Oka, M. Matsumoto, and K. Inagaki wrote the manuscript.
Otsuka Pharmaceutical Co., Ltd. was the sole funder of the studies described in the manuscript.

We declare that we all work as scientists employed by Otsuka Pharmaceutical Co., Ltd., the originator and owner of OPS-2071.

REFERENCES


